Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants

被引:543
作者
Aviram, M [1 ]
Rosenblat, M
Billecke, S
Erogul, J
Sorenson, R
Bisgaier, CL
Newton, RS
La Du, B
机构
[1] Rambam Med Ctr, Lipid Res Lab, Haifa, Israel
[2] Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Lipid Res Lab, Haifa, Israel
[3] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Vasc & Cardiac Dis, Ann Arbor, MI 48105 USA
[4] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Sch Med, Dept Anesthesiol, Ann Arbor, MI USA
关键词
paraoxonase; arylesterase; LDL; lipid peroxidation; antioxidants; glabridin; quercetin; free radicals; lysophosphatidylcholine; sulfhydryl group;
D O I
10.1016/S0891-5849(98)00272-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human serum paraoxonase (PON1) can protect low density lipoprotein (LDL) from oxidation induced by either copper ion or by the free radical generator azo bis amidinopropane hydrochloride (AAPH). During LDL oxidation in both of these systems, a time-dependent inactivation of PON arylesterase activity was observed. Oxidized LDL (Ox-LDL) produced by lipoprotein incubation with either copper ion or with AAPH, indeed inactivated PON arylesterase activity by up to 47% or 58%, respectively. Three possible mechanisms for PON inactivation during LDL oxidation were considered and investigated: copper ion binding to PON, free radical attack on PON, and/or the effect of lipoprotein-associated peroxides on the enzyme. As both residual copper ion and AAPH are present in the Ox-LDL preparations and could independently inactivate the enzyme, the effect of minimally oxidized (Ox-LDL produced by LDL storage in the air) on PON activity was also examined. Oxidized LDL, as well as oxidized palmitoyl arachidonoyl phosphatidylcholine (PAPC), lysophosphatidylcholine (LPC, which is produced during LDL oxidation by phospholipase A2-like activity), and oxidized cholesteryl arachidonate (Ox-CA), were all potent inactivators of PON arylesterase activity (PON activity was inhibited by 35%-61%). PON treatment with Ox-LDL (but not with native LDL), or with oxidized lipids, inhibited its arylesterase activity and also reduced the ability of the enzyme to protect LDL against oxidation. PON Arylesterase activity however was not inhibited when PON was pretreated with the sulfhydryl blocking agent, p-hydroxymercurybenzoate (PHMB). Similarly, on using recombinant PON in which the enzyme's only free sulfhydryl group at the position of cysteine-284 was mutated, no inactivation of the enzyme arylesterase activity by Ox-LDL could be shown. These results suggest that Ox-LDL inactivation of PON involves the interaction of oxidized lipids in Ox-LDL with the PON's free sulfhydryl group. Antioxidants such as the flavonoids glabridin or quercetin, when present during LDL oxidation in the presence of PON, reduced the amount of lipoprotein-associated lipid peroxides and preserved PON activities, including its ability to hydrolyze Ox-LDL cholesteryl linoleate hydroperoxides. We conclude that PON's ability to protect LDL against oxidation is accompanied by inactivation of the enzyme. PON inactivation results from an interaction between the enzyme free sulfhydryl group and oxidized lipids such as oxidized phospholipids, oxidized cholesteryl ester or lysophosphatidylcholine, which are formed during LDL oxidation. The action of antioxidants and PON on LDL during its oxidation can be of special benefit against atherosclerosis since these agents reduce the accumulation of Ox-LDL by a dual effect: i.e, prevention of its formation, and removal of Ox-LDL associated oxidized lipids which are generated during LDL oxidation. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:892 / 904
页数:13
相关论文
共 37 条
[1]   SERUM PARAOXONASE ACTIVITY, CONCENTRATION, AND PHENOTYPE DISTRIBUTION IN DIABETES-MELLITUS AND ITS RELATIONSHIP TO SERUM-LIPIDS AND LIPOPROTEINS [J].
ABBOTT, CA ;
MACKNESS, MI ;
KUMAR, S ;
BOULTON, AJ ;
DURRINGTON, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (11) :1812-1818
[2]  
ADKINS S, 1993, AM J HUM GENET, V52, P598
[3]  
AUGUSTINSSON KB, 1995, ACTA CHEM SCAND, V9, P383
[4]  
Aviram M, 1996, EUR J CLIN CHEM CLIN, V34, P599
[5]   PHOSPHOLIPASE A2-MODIFIED LDL IS TAKEN UP AT ENHANCED RATE BY MACROPHAGES [J].
AVIRAM, M ;
MAOR, I .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 185 (01) :465-472
[6]   Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities - Selective action of human paraoxonase allozymes Q and R [J].
Aviram, M ;
Billecke, S ;
Sorenson, R ;
Bisgaier, C ;
Newton, R ;
Rosenblat, M ;
Erogul, J ;
Hsu, C ;
Dunlop, C ;
La Du, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (10) :1617-1624
[7]   Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS ;
Primo-Parmo, SL ;
La Du, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1581-1590
[8]   Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS .
ATHEROSCLEROSIS, 1998, 138 (02) :271-280
[9]  
AVIRAM M, IN PRESS CURRENT REV
[10]   Structural aspects of the inhibitory effect of glabridin on LDL oxidation [J].
Belinky, PA ;
Aviram, M ;
Mahmood, S ;
Vaya, J .
FREE RADICAL BIOLOGY AND MEDICINE, 1998, 24 (09) :1419-1429